Physicians' Academy for Cardiovascular Education
Prof. Nicholls reviews what we have learned from previous studies with different CETP inhibitors, and presents details about studies with the ongoing CETP inhibitor obicetrapib.
"It has become apparent that the reduction in atherogenic lipoproteins drives CHD protection by CETP inhibition - not changes in HDL-c", says Prof. Kastelein. He explains this statement by findings from studies.
EAS 2022 Treatment with the CETP inhibitor obicetrapib resulted in a dose-dependent reduction of LDL-c after 8 weeks in patients enrolled in the ROSE trial. Obicetrapib had a good safety and tolerability profile.
EAS 2022 Prof. Ray shares the topline results of the ROSE trial, in which the effect of obicetrapib was examined in patients with elevated LDL-c despite high-intensity statin treatment.
Educational slides on the emerging role of CETP inhibition in the management of cardiovascular disease
The benefit of the CETP inhibitor anacetrapib on major coronary events increases with longer follow-up, shown in a post-trial analysis of patients who had been randomized to anacetrapib compared to those on placebo in the REVEAL trial.
AHA 2021 Treatment with the CETP inhibitor obicetrapib resulted in dose-dependent reduction of LDL-c after 8 weeks in patients enrolled in the ROSE trial. Obicetrapib had a good safety and tolerability profile.
In the past, there has been confusion about the relationship between HDL-c and CV risk and also between triglycerides and CV risk. Prof. Libby gives an update on what we know now about these lipids and CV risk.
EAS 2019 Emerging evidence reveals that "HDL" represents an enormously heterogeneous mixture of particles, with varying structural, compositional, metabolic and functional properties.
EAS 2019 Prof. Chapman is convinced that better understanding of HDL metabolism can lead to novel therapies, but we need to realize that it is much more complex than we have acknowledged thus far.
A Mendelian randomization study combined with metabolic biomarker analysis shows that CETP is an important causal determinant of HDL and VLDL concentration and composition.
VBWG at ACC 2018 Several novel targets have been discovered and new lipid-modifying therapies are being developed to prevent CVD, beyond LDL-c. Elliot Brinton discusses several of these, including omega-3 prescriptions, pemafibrate, apoC3, Lp(a), and shares the first trial results.
